Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametumumab + Anti-PD-1 + FOLFIRI in RAS WT Advanced CRC
NCT05684211Phase 2Unknown
- Sponsor
- Shanghai Celfuture Biotech
- Start
- Jan 2023
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ametumumab in colorectal cancer (CRC) (4 arms), sponsored by Shanghai Celfuture Biotech. Primary endpoint: Progression-Free Survival at 45 months. Status: unknown.
02
Drugs
ametumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05684211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05684211.